UNC School of Medicine Tests CAR T-Cell Therapy for Lupus
CAR T-cell therapy, a cancer treatment, is being tested in a clinical trial at the University of North Carolina School of Medicine, offering new hope for patients with lupus, an autoimmune disease.
Lima, OH, October 15, 2026 —
CAR T-cell therapy, a treatment used for cancer, is being tested in a clinical trial at the University of North Carolina School of Medicine for patients with lupus, an autoimmune disease. The trial is examining the therapy in a condition different from the cancer treatment context identified in the summary.
The development has been described as offering new hope for people with lupus. However, the information available does not include trial results or establish whether the treatment has been shown to help patients with the disease. Testing in a clinical trial is not, by itself, evidence of effectiveness.
Key details about the study were not provided, including its start date, the number of participants, its phase, the treatment protocol and the researchers leading the work. The available information also does not specify what outcomes the trial will measure or when findings may be reported.
As a result, the scope and status of the research cannot be assessed from the details provided. No conclusions about safety, effectiveness or availability for patients can be drawn from the summary alone. The confirmed information is limited to the institution, the therapy being tested, the clinical-trial setting and the condition under study.
Further information about the trial would be needed to clarify how the research is being conducted and what it may mean for people with lupus. Until results are reported, the study should be understood as a test of CAR T-cell therapy for the autoimmune disease, rather than evidence that the treatment is an established option for lupus.
Story summarized from the original created by Tisha Powell on www.hometownstations.com, see more information here.
Media gallery
